Atypical antipsychotic drug actions: Unitary or multiple mechanisms for 'atypicality'?

Clinical Neuroscience Research

Volumn 3, Issue 1-2, 2003, Pages 108-117

  Roth, Bryan L ^a   Sheffler, Douglas ^a   Potkin, Steven G ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 2 ADRENERGIC RECEPTOR; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; EPLIVANSERIN; FLUPERLAPINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE;

BRAIN CORTEX; BRAIN REGION; COGNITION; DISSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EUROPE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOOD; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; UNITED STATES;

EID: 0042029747     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(03)00021-5     Document Type: Review

References (91)

1. Kraeplin E. Dementia praecox 1919 Kreiger Publishing New York
2. Gaddum J.H. Hameed K.A. Drugs which antagonize 5-hydroxytryptamine Br J Pharmacol 9 1954 240-248
3. Wooley D.W. Shaw E. A biochemical and pharmacological suggestion about certain mental disorders Proc Natl Acad Sci USA 40 1954 228-231
4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1 1988 179-186
5. Seeman P. Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons Science 188 4194 1975 1217-1219
6. Creese I. Burt D.R. Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 4238 1976 481-483
7. Miller R.J. Hiley C.R. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism Nature 248 1974 546-547
8. Bolden C. Cusack B. Richelson E. Antagonism by anitmuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells J Pharmacol Exp Ther 260 1992 576-580
9. Hamon M. Nelson D.L. Herbet A. Glowinski J. Multiple receptors for serotonin in the rat brain Adv Biochem Psychopharmacol 21 1980 223-233
10. Newman-Tancredi A. Gavaudan S. Conte C. et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study Eur J Pharmacol 355 2-3 1998 245-256
11. Leysen J.E. Niemegeers C.J. Tollenaere J.P. Laduron P.M. Serotonergic component of neuroleptic receptors Nature 272 5649 1978 168-171
12. Roth B.L. Ciaranello R.D. Meltzer H.Y. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors J Pharmacol Exp Ther 260 3 1992 1361-1365
13. Roth B.L. Craigo S.C. Choudhary M.S. et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J Pharmacol Exp Ther 268 3 1994 1403-1410
14. Kohen R. Metcalf M.A. Khan N. et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor J Neurochem 66 1 1996 47-56
15. Peroutka S.J. U'Prichard D.C. Greenberg D.A. Snyder S.H. Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain Neuropharmacology 16 9 1977 549-556
16. Peroutka S.J. Synder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency Am J Psychiatry 137 12 1980 1518-1522
17. Kathmann M. Schlicker E. Gothert M. Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors Psychopharmacology (Berl) 116 4 1994 464-468
18. Nguyen T. Shapiro D.A. George S.R. et al. Discovery of a novel member of the histamine receptor family Mol Pharmacol 59 3 2001 427-433
19. Richelson E. Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds Life Sci 68 1 2000 29-39
20. Hippius H. A historical perspective of clozapine J Clin Psychiatry 60 Suppl 12 1999 22-23
21. Matz R. Rick W. Oh D. Thompson H. Gershon S. Clozapine - a potential antipsychotic agent without extrapyramidal manifestations Psychopharmacol Bull 11 1 1975 14
22. Matz R. Rick W. Thompson H. Gershon S. Clozapine - a potential antipsychotic agent without extrapyramidal manifestations Curr Ther Res Clin Exp 16 7 1974 687-695
23. Fink H. Morgenstern R. Oelssner W. Clozapine - a serotonin antagonist? Phamacol Biochem Behav 20 1984 513-517
24. Reynolds G.P. Garrett N.J. Rupniak N. Jenner P. Marsden C.D. Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors Eur J Pharmacol 89 3-4 1983 325-326
25. Remington G. Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 148 1 2000 3-15 [see comments]
26. Kane J. Honigfield G. Singer J. Meltzer H.Y. Group atCCS. Clozapine for the treatment-resistant schizophrenic Arch Gen Psychiatry 45 1988 789-796
27. Meltzer H.Y. Suicide in schizophrenia: risk factors and clozapine treatment J Clin Psychiatry 59 Suppl 3 1998 15-20
28. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics J Psychiatry Neurosci 25 2 2000 137-153
29. Meltzer H.Y. Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial J Clin Psychiatry 60 Suppl 12 1999 47-50
30. Haupt D.W. Newcomer J.W. Hyperglycemia and antipsychotic medications J Clin Psychiatry 62 Suppl 27 2001 15-26 [discussion 40-1]
31. Meatherall R. Younes J. Fatality from olanzapine induced hyperglycemia J Forensic Sci 47 4 2002 893-896
32. Straker D. Mendelowitz A. Karlin L. Near fatal ketoacidosis with olanzapine treatment Psychosomatics 43 4 2002 339-340
33. Ananth J. Venkatesh R. Burgoyne K. Gunatilake S. Atypical antipsychotic drug use and diabetes Psychother Psychosom 71 5 2002 244-254
34. Zeng X.P. Le F. Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs Eur J Pharmacol 321 3 1997 349-354
35. Meltzer H.Y. Matsubara S. Lee J.-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J Pharmacol Exp Ther 251 1989 238-246
36. Inoue T. Domae M. Yamada K. Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland J Pharmacol Exp Ther 277 1 1996 137-143
37. Jordan S. Koprivica V. Chen R. Tottori K. Kikuchi T. Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor Eur J Pharmacol 441 3 2002 137-140
38. Burris K.D. Molski T.F. Xu C. et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 1 2002 381-389
39. Lawler C.P. Prioleau C. Lewis M.M. et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 20 6 1999 612-627
40. Inoue A. Miki S. Seto M. et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum Eur J Pharmacol 321 1 1997 105-111
41. Kapur S. Zipursky R. Remington G. Jones C. McKay G. Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia Am J Psychiatry 154 11 1997 1525-1529
42. Herrick-Davis K. Grinde E. Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine 2C receptors J Pharmacol Exp Ther 295 1 2000 226-232
43. Carlsson A. Waters N. Carlsson M.L. Neurotransmitter interactions in schizophrenia - therapeutic implications Eur Arch Psychiatry Clin Neurosci 249 Suppl 4 1999 37-43
44. Roth B.L. Shapiro D.A. Insights into the structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development Expert Opin Ther Targets 5 2001 685-695
45. 2A receptors in atypical antipsychotic drug actions Neuroscientist 5 1999 254-262
46. Meltzer H.Y. The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 Suppl 2 1999 106S-115S
47. Hollister L.E. Drug-induced psychoses and schizophrenic reactions, a critical comparison Ann NY Acad Sci 96 1962 80-88
48. Willins D. Deutch A. Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex Synapse 27 1997 79-82
49. Jakab R. Goldman-Rakic P. 5-hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites Proc Natl Acad Sci USA 95 1998 735-740
50. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders Biol Psychiatry 51 10 2002 775-787
51. Sorensen S.M. Kehne J.H. Fadayl E.M. et al. Characterization of the 5-HT2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies J Pharmacol Exp Ther 266 1993 684-691
52. Martin P. Waters N. Waters S. Carlsson A. Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride Eur J Pharmacol 335 2-3 1997 107-116
53. Araneda R. Andrade R. 5-hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex Neuroscience 40 2 1991 399-412
54. Aghajanian G.K. Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells Neuropharmacology 36 4-5 1997 589-599
55. Martin P. Waters N. Schmidt C.J. Carlsson A. Carlsson M.L. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone J Neural Transm 105 4-5 1998 365-396
56. Bubser M. Backstrom J.R. Sanders-Bush E. Roth B.L. Deutch A.Y. Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum Synapse 39 4 2001 297-304
57. Nocjar C. Roth B.L. Pehek E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group Neuroscience 111 1 2002 163-176
58. Ikemoto K. Nishimura A. Okado N. Mikuni M. Nishi K. Nagatsu I. Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration Brain Res 853 2 2000 377-380
59. Yan Q.S. Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission Brain Res Bull 51 1 2000 75-81
60. Pehek E.A. McFarlane H.G. Maguschak K. Price B. Pluto C.P. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex Brain Res 888 1 2001 51-59
61. Miner L.A.H. Backstrom J.R. Sanders-Bush E. Sesack S.R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex Neuroscience 116 1 2003 107-117
62. Gray J.A. Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists Brain Res Bull 56 5 2001 441-451
63. Berry S. Shah M. Khan N. Roth B. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro Mol Pharmacol 50 2 1996 306-313
64. Bhatnagar A. Willins D.L. Gray J.A. Woods J. Benovic J.L. Roth B.L. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis J Biol Chem 276 11 2001 8269-8277
65. Gray J.A. Roth B.L. Cell biology. A last GASP for GPCRs? Science 297 5581 2002 529-531
66. Hanley N.R. Hensler J.G. Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor J Pharmacol Exp Ther 300 2 2002 468-477
67. Gray J.A. Sheffler D.J. Bhatnagar A. et al. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells Mol Pharmacol 60 5 2001 1020-1030
68. Willins D. Berry S. Alsayegh L. Backstrom J. Sanders-Bush E. Roth B.L. Clozapine and other 5-hydroxytryptamine2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine2A receptors in vitro and in vivo Neuroscience 91 1999 599-606
69. Strauss W.H. Klieser E. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study Eur J Neuropsychopharmacol 1 1991 101-105
70. Duinkerke S.J. Botter P.A. Jansen A.A. et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial Br J Psychiatry 163 1993 451-455
71. Wiesel F.A. Nordstrom A.L. Farde L. Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia Psychopharmacology (Berl) 114 1 1994 31-38
72. Rinaldi-Carmona M. Congy C. Santucci V. et al. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist J Pharmacol Exp Ther 262 2 1992 759-768
73. Kapur S. Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics[quest ]: a new hypothesis Am J Psychiatry 158 3 2001 360-369
74. Kapur S. Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action J Psychiatry Neurosci 25 2 2000 161-166
75. Daniel D.G. Wozniak P. Mack R.J. McCarthy B.G. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group Psychopharmacol Bull 34 1 1998 61-69
76. Shore D. Clinical implications of clozapine discontinuation: report of an NIMH workshop Schizophr Bull 21 2 1995 333-338
77. Thurstone C.C. Alahi P. A possible case of quetiapine withdrawal syndrome J Clin Psychiatry 61 8 2000 602-603
78. Curran M.P. Perry C.M. Amisulpride: a review of its use in the management of schizophrenia Drugs 61 14 2001 2123-2150
79. Schoemaker H. Claustre Y. Fage D. et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity J Pharmacol Exp Ther 280 1 1997 83-97
80. Leucht S. Pitschel-Walz G. Engel R.R. Kissling W. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials Am J Psychiatry 159 2 2002 180-190
81. Lewander T. Westerbergh S.E. Morrison D. Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial programme Acta Psychiatr Scand Suppl 358 1990 92-98
82. Wadworth A.N. Heel R.C. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia Drugs 40 6 1990 863-879
83. Oshiro Y. Sato S. Kurahashi N. et-al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives J Med Chem 41 5 1998 658-667
84. Ozdemir V. Fourie J. Ozdener F. Aripiprazole (Otsuka Pharmaceutical Co) Curr Opin Investig Drugs 3 1 2002 113-120
85. Yokoi F. Grunder G. Biziere K. et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride Neuropsychopharmacology 27 2 2002 248-259
86. Kalkman H.O. Neumann V. Hoyer D. Tricklebank M.D. The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat Br J Pharmacol 124 7 1998 1550-1556
87. Hertel P. Fagerquist M.V. Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade Science 286 5437 1999 105-107
88. Litman R.E. Su T.P. Potter W.Z. Hong W.W. Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine Br J Psychiatry 168 5 1996 571-579
89. Meltzer H.Y. Alphs L. Green A.I. Altamura A.C. Anand R. Bertoldi A. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry 60 1 2003 82-91
90. Kroeze W.K. Hufeisen S.J. Popadak B.A. Renock S.M. Steinberg S. Ernsberger P. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology 28 3 2003 519-526
91. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, Roth BL, Mailman RB. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol http://www.acnp.org/citations/Npp032703396/default.pdf